Tier 1 — highest

Broccoli Sprout Extract for Glycemic Management in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Trial

Carla Maria Avesani, Oskar Swartling, Anders H Rosengren, Olof Heimbürger, Maria K Svensson, Gregor Guron, Mårten Segelmark, Vaida Petrauskiene, Sigrid Lundberg, Andreas Jonsson, Josefin Mörtberg, Oscar Bratt, Ursa Bonnevier, Anders Fernstrom, Fredrik Uhlin, Maria Carlström, Babak Ghajavand, Anders Christensson, Roberta Fontanive Miyahira, Marie Evans, Peter Stenvinkel, INITIATE study group and the SNephR Network
Journal of Renal Nutrition 2026 Published online August 25, 2026

Bibliography

PubMed
PMID 42641715
DOI
10.1053/j.jrn.2026.08.009
Funding
Supported by the Swedish Scientific Council (2019-06103), Region Stockholm CIMED Research grant FoUI-963364, Njurfonden, and the Martin Rind Foundation.

Study snapshot

DesignMulticenter randomized double-blind placebo-controlled clinical trial
ModelAdults with type 2 diabetes and chronic kidney disease stages 3b-4
Sample99 randomized; 91 completed
InterventionIncremental broccoli sprout extract dosing, reported in the abstract as 50 to 150 µmol/day BSE, versus placebo.
Duration12 weeks of intervention plus 8 weeks without intervention
EndpointsFasting glucose; Insulin; HbA1c; Glycemic control; Follow-up after intervention

What the study showed, in plain terms

This 2026 multicenter trial tested whether broccoli sprout extract improves glucose control in older adults with both type 2 diabetes and moderate-to-severe chronic kidney disease.

Key findings

The trial found no statistically significant between-group improvements in fasting glucose, insulin or HbA1c after 12 weeks, and no significant benefit at the 21-week end-of-study follow-up in either intention-to-treat or per-protocol analyses.

What this study can and cannot tell us

The population was older and had CKD stages 3b-4, so the null result does not automatically negate findings in other type 2 diabetes populations. The abstract's dose wording is internally difficult to interpret, so dose conversions should not be inferred beyond the authors' reported BSE dosing.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology